

Original article

Synthesis, Characterization and Biological Evaluation of Pyrazolyl Aminopyrimidine Derivatives

Deepthi Reddy*, Akhila Pera, B Gayatri, Boyeni Lakshmi Yadav, Chegoni Likhitha, B Manisha

Department of Pharmaceutical Chemistry, Bojjam Narasimhulu Pharmacy College for Women, Vinaynagar, Saidabad. Hyderabad-500059, India.

ARTICLE INFO:

Received: 11 Feb 2022

Accepted: 26 Feb 2022

Published: 28 Feb 2022

Corresponding author *

Deepthi Reddy,
Department of Pharmaceutical
Chemistry, Bojjam Narasimhulu
Pharmacy College for Women,
Vinaynagar, Saidabad.
Hyderabad-500059, India
E Mail:
deepurdy.reddy57@gmail.com

ABSTRACT:

A new series of pyrazolyl aminopyrimidine derivatives 5a-5d had been synthesized and tested for antimicrobial agents against different bacteria and fungi and anti-inflammatory activity in the Carrageenan induced acute inflammation in rats. The structures of new sulfanilamide derivatives were characterized by NMR spectroscopy and mass spectrometry. The synthesized compounds were tested for their in vitro antimicrobial activity using the broth diffusion method against Gram-positive bacteria *S. Aureus*, *S. Pyogenus* the Gram-negative bacteria *E. Coli*, *P. Aeruginosa*, the fungal strain *C.Albicans*, *A. Niger*, *A. clavatus*. It has been observed that the maximum anti-inflammatory activity was recorded by compound 5a having 65.38% percentage protection of edema followed by compound 5b (60.25 %), 5c (50 %) & 45 (39.74%) anti-inflammatory potential. The compound 5a showed more percentage protection of edema than that of the standard drug Diclofenac sodium.

Keywords: Antibacterial, Antifungal, Griseofulvin, Anti-inflammatory activity.

1. INTRODUCTION

Inflammatory diseases can affect the quality of life of many patients; however, the current medicinal drugs are not always effective and may cause serious adverse effects [1]. Nonetheless, infectious diseases are among the leading causes of death globally, and antimicrobial resistance has been commonly reported worldwide [2, 3]. These obstacles necessitate the search for new therapies with potential antioxidant, anti-inflammatory, and antimicrobial activities. Despite massive efforts by various global academic and industrial research laboratories over the years, developing anti-inflammatory and antimicrobial agents that are potent, safe, and selective remains quite challenging. The pyrimidine ring is responsible for the properties of many natural and synthetic biomolecules. The pyrimidine ring is a key structural moiety of life-supporting substances, such as vitamins, coenzymes, and uric acid, as well as of drugs, such as Veronal, Sulfadiazine, Fluorouracil, Glivec, and Rosuvastatin. Since the aminopyrimidine ring is a fragment of nucleotide bases in DNA and RNA, which are the most important components of living cells, the significance of these compounds in the nature can scarcely be overestimated.

The pyrimidine structural motif is a fundamental part of nucleic acids and associated with numerous biological activities [4]. Substituted aminopyrimidine nuclei are common in the marketed drugs such as anti-atherosclerotic Aronixil[®], anti-histaminic Thonzylamine[®] (I), anti-anxiolytic Buspirone[®] (II), anti-psoriatic Enazadrem[®] (III), and other medicinally relevant compounds [5].

The discovery of a series of aminopyrimidine derivatives inhibiting the protein kinases is one of the most important advances in the field of synthetic chemistry of aminopyrimidines. Some other biological activities of these molecules include antitubercular, adenosine receptor antagonists [6], analgesic [7] and anti-inflammatory [9].

Previous reports have suggested that beginning with modification of compounds known to have pharmacological effects or conjugating two structures with promising biological effects into an interesting motif may be useful for developing new effective therapeutic agents. Therefore, this work aimed to design and synthesise new pyrazolyl aminopyrimidine derivatives [8], in order to evaluate their anti-inflammatory and antimicrobial activities against medically important bacterial and fungal strains. In this study the aim is obtaining compounds with more powerful desired effects.

2. EXPERIMENTAL

2.1 Materials

All chemicals and reagents were used are of analytical grade. Melting points were determined on an electro thermal apparatus using open capillaries and are uncorrected. Thin-layer chromatography was accomplished on 0.2-mm pre-coated plates of silica gel G60 F254 (Merck). Visualization was made with UV light (254 and 365nm) or with an iodine vapor. ¹H NMR spectra were recorded on a Bruker DPX-400 MHz spectrometer. Chemical shifts are expressed in ppm downfield from TMS as an internal standard.

2.2 Synthesis Procedure

2.2.1 General procedure for the synthesis of pyrazolic chalcones(3a-e)

To a solution of acetophenones (1a-e)(10 mmol) and phenylhydrazine (10 mmol) in EtOH (10 mL) was added a drop of concentrated H₂SO₄ and the resultant solution was refluxed for 2 h. On cooling, precipitates(2a-e) were filtered, washed with cold EtOH and dried, provided sufficiently pure (by TLC) hydrazone, which were immediately used for the next step. POCl₃ (15 mmol) was added drop wise to dry DMF (15 mmol) in round bottom flask at 0 °C and the resultant mixture was stirred for 30 minutes until the formation of Vilsmeier-Haack reagent appeared. The corresponding solution of phenylhydrazones (2a-e) (5 mmol) in minimum amount of dry DMF were added dropwise to the Vilsmeier-Haack reagent, which were warmed at r.t. and heated at 70- 80 °C for 5 h. The cool reaction mixture was poured into crushed ice and neutralized with a cool saturated K₂CO₃ solution. The precipitates were filtered, strongly washed with water and crystallized from ethanol, affording pure 3a-e.

2.2.2 General procedure for the synthesis of pyrazolic chalcones (4a-e)

A mixture of 3-aryl-1-phenylpyrazol-4-carboxaldehydes 3a-e (10 mmol) and 3-acetyl pyridine (10 mmol) were stirred in methanolic sodium hydroxide solution for 24 h at room temperature. Upon completion, the precipitates formed were filtered off, washed with water and dried, affording compounds 4a-e. The compounds were crystallized from ethanol

2.2.3 General procedure for the synthesis of compounds (5a-e)

A mixture of (E)-3-(3(aryl)-1-phenyl-1H-pyrazol-4-yl)-1-(pyridin-3-yl) prop-2-en-1- ones 4a-e (5 mmol) and guanidine hydrochloride (5 mmol) in ethanolic KOH (3%, 20 ml) was refluxed for 10 h. On completion, the reaction mixture was allowed to stand overnight. The precipitates were filtered off, washed with water and dried, affording compounds 5a-e. The compounds were re-crystallized in ethanol.

4-(1,3-Diphenyl-1H-pyrazol-4-yl)-6-(pyridine-3-yl) pyrimidine-2-amine (5a)

IR (neat, max cm⁻¹): 3312, 3149, 1655, 1573, 1544, 1503

¹H NMR (300 MHz, CDCl₃): 8.87 (s, 1H), 8.60-8.64 (m, 1H), 8.59 (s, 1H), 7.28-8.08 (m, 12 H), 6.92 (s, 1H), 5.18 (s, 2H); ¹³C NMR (125 MHz, DMSO-d₆): 164.36, 162.30, 161.54, 151.57, 151.34, 148.33, 139.59, 134.45, 133.36, 133.23, 130.54, 130.13, 129.36, 128.82, 128.67, 127.35, 124.21, 121.53, 119.08, 104.93;

Anal. Calcd. for C₂₄H₁₈N₆: C, 73.83; H, 4.65; N, 21.52. Found: C,73.75; H, 4.59; N, 21.48; MS (ESI) [M + H]⁺ Calcd. for C₂₄H₁₈N₆: 391.44, Found:391.4 [M + H]⁺.

4-(3-(4-Fluorophenyl)-1-phenyl-1H-pyrazol-4-yl)-6-(pyridine-3-yl) pyrimidin-2- amine (5b)

IR (neat, max cm⁻¹): 3320, 3160, 1655,1577, 1547, 1510; ¹H NMR (300 MHz, CDCl₃): 8.95 (s, 1H), 8.65-8.66 (m, 1H), 8.56 (s, 1H), 7.13-8.11 (m, 11 H), 6.95 (s, 1H), 5.13 (s, 2H);

¹³C NMR (125 MHz, DMSO-d₆): 164.26, 163.63, 162.42, 161.68, 161.45, 151.60, 150.37, 148.42, 139.54, 134.51, 133.23, 131.62, 131.55, 130.87, 130.14, 129.80, 129.78, 127.41, 124.23, 121.34, 119.07, 115.53, 115.36, 104.81

Anal. Calcd. for C₂₄H₁₇FN₆: C,70.58, 4.20; N, 20.58. Found: C, 70.61; H, 4.16; N, 20.54; MS (ESI) [M + H]⁺ Calcd. for C₂₄H₁₈FN₆: 409.43. Found: 409.6 [M + H]⁺.

4-(3-(4-Chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)-6-(pyridine-3-yl)pyrimidin-2- amine (5c)

IR (neat, max cm⁻¹): 3324, 3164,1652, 1585, 1547, 1506; ¹H NMR (300 MHz, CDCl₃): 8.99 (s, 1H), 8.7 (d, J = 3.3 Hz, 1H), 8.54 (s, 1H), 8.10 (d, J = 7.5 Hz, 1H), 7.82 (d, J = 7.8 Hz, 2H), 7.66 (d, J = 8.1 Hz, 2H), 7.35-7.52 (m, 6H), 6.96 (s, 1H), 5.13 (s, 2H);

¹³C NMR (125 MHz, DMSO-d₆): 164.25, 162.49, 161.40, 151.61, 150.04, 148.46, 139.50, 134.54, 133.43, 133.22, 132.19, 131.19, 131.11, 130.15, 128.58, 127.48, 124.23, 121.47, 119.11, 104.89

Anal. Calcd. for C₂₄H₁₇ClN₆: C, 67.84; H, 4.03; N, 19.78. Found: C,67.86; H, 4.04; N, 19.81;

MS (ESI) [M + H]⁺ Calcd. for C₂₄H₁₈ClN₆: 425.88, Found:425.5 [M + H]⁺.

4-(3-(3-Bromophenyl)-1-phenyl-1H-pyrazol-4-yl)-6-(pyridine-3-yl) pyrimidin-2- amine(5d)

IR (neat, max cm⁻¹): 3335, 3204, 1648, 1585,1566, 1536 ¹H NMR (300 MHz, CDCl₃): 8.97 (s, 1H), 8.66 (d, J = 4.8 Hz, 1H), 8.57 (s, 1H), 8.13 (d, J = 7.8 Hz, 1H), 7.95 (s, 1H), 7.82 (d, J = 7.5 Hz, 2H), 7.27-7.64 (m, 7H), 6.98 (s, 1H), 5.13 (s, 2H);

¹³C NMR (125 MHz, DMSO-d₆): 164.26, 162.54, 161.28, 151.63, 149.54, 148.44, 139.46, 135.61, 134.54, 133.19, 131.58, 131.46, 131.10, 130.75, 130.16, 128.47, 127.56, 124.23, 121.78, 121.55, 119.18, 104.96

Anal. Calcd. for C₂₄H₁₇BrN₆: C, 61.42, H, 3.65; N, 17.91. Found: C, 61.39; H, 3.64;N, 17.89;

MS (ESI) [M]⁺ Calcd. for C₂₄H₁₇BrN₆: 469.34, Found: 469.5 [M]⁺.

4-(3-(4-Bromophenyl)-1-phenyl-1H-pyrazol-4-yl)-6-(pyridine-3-yl)pyrimidin-2-amine (5e)

IR (neat, max cm⁻¹): 3324, 3164, 1652,1581, 1547, 1503;

¹H NMR (300 MHz, CDCl₃): 8.00 (s, 1H), 8.66-8.68 (m, 1H), 8.53 (s, 1H), 8.08-8.11 (m, 1H), 7.81 (d, J = 7.5, 2H), 7.33-7.59 (m, 8H), 6.96 (s, 1H), 5.17 (s, 2H);

¹³C NMR (125 MHz, DMSO-d₆): 164.26, 162.49, 161.40, 151.62, 150.07, 148.47, 139.50, 134.54, 133.22, 132.56, 131.50, 131.47, 131.16, 130.16, 127.49, 124.22, 122.12, 121.47, 119.11, 104.90;

Anal. Calcd. for C₂₄H₁₇BrN₆: C, 61.42; H, 3.65; N, 17.91.

Found: C, 61.39; H, 3.64; N, 17.87;

MS (ESI) [M + H]⁺ Calcd. for C₂₄H₁₇BrN₆: 471.34. Found: 471.3 ([M + H]⁺ + 1).

2.3 Antimicrobial activity

Antimicrobial Study Agar well-diffusion method was applied to study the antimicrobial activity of the synthesized pyrazoline derivatives (P1-P4) against Escherichia coli (MTCC 443) and Pseudomonas aeruginosa (MTCC 441) from gram negative group of bacteria while Staphylococcus aureus (MTCC 96) and Streptococcus pyogenus (MTCC 442) from gram positive group of bacteria. The *in vitro* antifungal activity of all compounds and standard drugs were evaluated against three fungi viz. Candida albicans (MTCC 227) Aspergillus niger (MTCC 282) and Aspergillus clavatus (MTCC 1323). Table 3 and Table 4. The concentration for each compound was 2 mg/ml, using DMSO as a solvent and control. Ampicillin and Griseofulvin was used as standard drug for anti-bacterial and antifungal activity respectively. For all synthesized compound the minimum inhibitory concentration and zone of inhibition were measured against all tested microorganism.

2.4 Anti-inflammatory Activity


The anti-inflammatory activity was assessed as suggested by Winter *et al* [10] by using carrageenan as edematogenic agent on adult albino rats of either sex weighing between 125- 150g. The selected albino rats were housed in groups of six each in acrylic cages under laboratory conditions. The test compounds 5a, 5b, 5c, 5d and 5e were administered intraperitoneally in the form of suspension with tween-40 and normal saline at a dose of 50mg/kg b.w. The Diclofenac sodium 10mg/kg was used as reference standard and administered in a similar manner. The control group received the solvent (tween-40 + normal saline) at 2ml/kg b.w. in a similar manner. All the test samples were administered 30mins before injection of carrageenan (0.1ml of 1% w/v in normal saline) into the sub-plantar region of left hind paw of each rat. The contra-lateral paw was injected with an equal volume of saline. The increase in paw swelling (volume) was determined by plethysmometer by calculating the difference between the volumes of the mercury displaced by the two paws in ml. The increase in paw volume was measured at 1, 2 & 3 hrs after the administration of the test compounds. The percentage protection of edema was calculated at the end of 3 hrs as per the following formula.

$$\% \text{ of protection} = \frac{P_c - P_T}{P_c} \times 100$$

Where P_c = Increase in paw volume at time 't' of solvent control & P_T = Increase in paw volume at time 't' of test.

3. RESULT AND DISCUSSION

3.1. Current working scheme



a: R = H, b: R = 4-F, c: R = 4-Cl, d: R = 3-Br, R = 3- NO₂

Table 1: Physicochemical character of synthesized compound

Sl. No.	Compound	Molecular formula	Molecular weight	% of yield	Melting point (°C)	Nature
1	5a	C ₂₄ H ₁₈ N ₆	391.44	74	238-240	Light yellow solid
2	5b	C ₂₄ H ₁₈ FN ₆	409.43	76	258-260	Yellow solid
3	5c	C ₂₄ H ₁₈ ClN ₆	425.88	69	266-268	Light yellow solid
4	5d	C ₂₄ H ₁₇ BrN ₆	479.34	83	240-242	White solid
5	5e	C ₂₄ H ₁₇ BrN ₆	471.34	79	242-244	Light yellow

Table 2: Elemental analysis of synthesized compound

Compound	Molecular formula	Calculated (%)			Found (%)		
		C	H	N	C	H	N
5a	C ₂₄ H ₁₈ N ₆	73.83	4.65	21.52	73.75	4.59	21.48
5b	C ₂₄ H ₁₈ FN ₆	70.58	4.20	20.58	70.61	4.16	20.54
5c	C ₂₄ H ₁₈ ClN ₆	67.84	4.03	19.78	67.86	4.04	19.81
5d	C ₂₄ H ₁₇ BrN ₆	61.42	3.65	17.91	61.39	3.64	17.89
5e	C ₂₄ H ₁₇ BrN ₆	61.42	3.65	17.91	61.39	3.64	17.87

3.2. Antimicrobial activity (5a-5e)

In antibacterial potency compounds 4a and 4b were found to be equipotent to Ampicillin while compound 4c was found as more potent than Ampicillin against *E. coli*. Compound 4b found to be more potent than ampicillin against *P. Aeruginosa*. Compound 5d was found to be equivalent to ampicillin and compound Pc and 5d found to be more potent than ampicillin against gram positive bacteria *S. Aureus*. Compound 5c found to be equivalent to ampicillin against gram positive bacteria *S. Pyogenus*. Physicochemical properties also mentioned in Table 1.

In antifungal activity compounds 5c and 5d found to be equivalent to Griseofulvin against *C. Albicans* and all four compounds were found to be less potent than Griseofulvin against *A. Niger* and *A. Clavatus*.

Table 3: Antibacterial activity screening

Compound	Minimum Inhibition Concentration (MIC, µg/mL)			
	Gram-negative		Gram-positive	
	<i>E. Coli</i>	<i>P. Aeruginosa</i>	<i>S. Aureus</i>	<i>S. Pyogenus</i>
5a	100	200	250	200
5b	100	62.5	500	500
5c	50	125	100	100
5d	200	250	100	250
5e	100	62.5	500	500
Ampicillin	100	100	250	100

Table 4: Antifungal activity screening

Compound	Minimum Inhibition Concentration (MIC, µg/mL)		
	<i>C. Albicans</i>	<i>A. Niger</i>	<i>A. Clavatus</i>
5a	1000	1000	1000
5b	1000	250	500
5c	500	500	1000
5d	500	500	1000
5e	1000	250	500
Greseofulvin	500	100	100

3.3. Anti-inflammatory activity (5a-5e)

The anti-inflammatory activity of present synthesized compounds was evaluated by carrageenan induced acute inflammatory method in rats on comparison with standard diclofenac sodium. The result revealed that the all-synthesized compounds shown anti-inflammatory activity (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$) when compare to control and positive control group (Table 5). These showed the percentage protection of edema ranges between 39.74 and 65.38 at the end of 3 hrs; where as the standard drug Diclofenac sodium registered 64.10% (Table 2). It has been observed that the maximum anti-inflammatory activity was recorded by the compound **5a** having 65.38% percentage protection of edema followed by compound **5b** (60.25 %), **5c** (50 %) & **5d** (39.74%) anti-inflammatory potential. The compound **5a** showed more percentage protection of edema than that of standard drug Diclofenac sodium. It has been found that the extent of increase in paw volume reduces significantly up to 3 hrs when compared with solvent control.

Table 5: Anti-inflammatory activity of pyrazolyl aminopyrimidine (5a, 5b, 5c, 5d and 5e)

Sl. No.	Compound	Increase in paw vol (ml)			% Protection at 3h
		1h	2h	3h	
1	Solvent	0.48±0.02	0.73±0.03	0.78±0.01	---
2	5a	0.24±0.03***	0.29±0.01***	0.27±0.03***	65.38
3	5b	0.36±0.03**	0.49±0.06**	0.47±0.02***	39.74
4	5c	0.27±0.03***	0.34±0.05***	0.31±0.05***	60.25
5	5d	0.29±0.02***	0.40±0.01***	0.39±0.05***	50.00
6	5e	0.31±0.03**	0.42±0.05**	0.41±0.004**	41.72
6	Diclofenac	0.38±0.02**	0.33±0.04***	0.28±0.03***	64.10

Values expressed as Mean ± SEM, n=6, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, Dose of the test compound: 50 mg/kg.

4. CONCLUSION

The present study concluded the beneficial effect of synthesized novel pyrazolyl aminopyrimidine derivatives as

antimicrobial agent against different bacteria and fungi and in the Carrageenan induced acute inflammation in rats. This study confirms the rational basis for its use in synthesized novel pyrazolyl aminopyrimidine and its derivatives for the treatment of microbial infection and inflammation in patients. Further pharmacological investigations are under way to characterize active novel pyrazolyl aminopyrimidine and to establish exact mechanism of antimicrobial and anti-inflammation action, which may have fewer side effects. This work, we believe, will be useful for further antimicrobial and inflammation research works.

4. REFERENCES

- Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, Li Y, Wang X, Zhao L. Inflammatory responses and inflammation-associated diseases in organs. *Oncotarget*. 2018;9:7204.
- Pal C, Bengtsson-Palme J, Kristiansson E, Larsson DJ. The structure and diversity of human, animal and environmental resistomes. *Microbiome*. 2016;4:1-5.
- Laxminarayan R, Duse A, Wattal C, *et al.* Antibiotic resistance—the need for global solutions. *Lancet Infect Dis*. 2013;13:1057-98.
- Sayle KL, Bentley J, Boyle FT, *et al.* Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2. *Bioorg Med Chem Lett*. 2003;13:3079-82.
- Roy H, Chakraborty A, Bhanja S, Nayak BS, Mishra SR, Ellaiah P. Preliminary phytochemical investigation and anthelmintic activity of *Acanthospermum hispidum* DC; *Journal of Pharmaceutical Science and Technology*, 2010, 2, 217-221.
- Hughes TV, Emanuel SL, Beck AK, *et al.* 4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: Synthesis and biological evaluation. *Bioorg Med Chem Lett* 2007;17:3266-70.
- Gasse C, Douguet D, Huteau V, *et al.* Substituted benzyl-pyrimidines targeting thymidine monophosphate kinase of *Mycobacterium tuberculosis*: synthesis and in vitro anti-mycobacterial activity. *Bioorganic & medicinal chemistry*. 2008;16:6075-85.
- Ishibl, H.M.; Al-Abdullah, E.S.; Haiba, M.E. Coumarin Derivatives. U.S. Patent Application Pending no. 16/399,950, 30 April 2019.
- Fatima F, Bhat SH, Ullah MF, Abu-Duhier F, Husain E. In-Vitro Antimicrobial Activity of Herbal Extracts From Tabuk Region (Kingdom of Saudi Arabia) Against Nosocomial Pathogens: A Preliminary Study. *Global Journal of Health Science*. 2018;10:1-83.
- Winter CA, Risley EA, Nuss GW. Carrageenin-induced edema in hind paw of the rat as an assay for antiinflammatory drugs. *Proceedings of the society for experimental biology and medicine*. 1962;111:544-7.

ACKNOWLEDGEMENT: None.

CONFLICT OF INTEREST: The authors declare no conflict of interest, financial or otherwise.

SOURCE OF FUNDING: None.

AVAILABILITY OF DATA AND MATERIALS: Not applicable.

CONSENT FOR PUBLICATION: Not applicable.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Not applicable